Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 899

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 899
---
 Rochelle, NY 10805 | United States

Newbridge Securities Corporation (“Newbridge,” “we,” “us” or “our”) understands that FutureTech II Acquisition Corp. (NASDAQ:FTII), a publicly traded blank check company incorporated as a Delaware corporation (“FTII”), is considering a business combination with Longevity Biomedical, Inc., a privately-heldDelaware
corporation (the “Company” or “Longevity”, and together with FTII, collectively, the
“Parties”).

| ■ | Pursuant                                                                                                                             
 to the terms of that certain business combination agreement, by and among Longevity, FTII and the other parties thereto, the Parties 
 intend to effect a business combination transaction whereby (a) LBI Merger Sub, Inc., a Delaware corporation (“Merger Sub”)          
 and a wholly-owned subsidiary of FTII”), will merge with and into Company, with Company being the surviving entity and becoming      
 a wholly-owned subsidiary of FTII, in accordance with the applicable provisions of the Delaware General Corporation Law (the “DGCL”) 
 (the Business Combination Agreement, together with the other transactions contemplated thereby, the “Transactions”).                 |
| ■ | In                                                                                                                                   
 full payment for the purchased shares, the stockholders of Longevity shall collectively be entitled to receive from FTII, in the     
 aggregate, a number of shares of FTII Common Stock with an aggregate value equal to (a) (i) $100,000,000 less (ii) the Converted     
 Stock Option Value, if any, divided by (b) $10.00 (the “Merger Consideration”).                                                      |

The Board of Directors of FTII has retained Newbridge to render an opinion (the “Opinion”) as to whether, on the date of such Opinion, (i) the Merger Consideration is fair, from a financial point of view, to FTII’s public stockholders and (ii) the Company has an aggregate fair market value equal to at least eighty percent (80.0%) of the assets held by FTII in its trust account (the “Trust Account”) for the benefit of FTII’s public stockholders (excluding taxes payable on the interest earned on the Trust Account).

We have not been requested to opine on, and our Opinion does not in any manner address, the underlying business decision of FTII to proceed with the Transactions. In addition, we have not been requested to explore any alternatives to the Transactions. Further, our Opinion does not address